SBIR/STTR Research Award
Controlled Gradient Release of Biologics: Enhanced Nerve Conduit for Long‐Gap Injury Repair
Award amount
$636,547Program and phase
STTR · Phase IAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Pioneer Neurotech Inc.
- Proposal award date
- 2023-08-01
- Contract end date
- 2025-07-31
- UEI
- HXJXFZVH8RZ1
- Solicitation number
- PA21-262
- Topic code
- 106
Research abstract
Project Summary / Abstract Nerve injuries arising from trauma, disease, or as a surgical necessity, lead most often to permanent loss of some or all functions mediated by the injured nerves. 50,000 peripheral nerve procedures are performed every year in the US, and 300,000 across Europe. After complete transection of a nerve, the optimal clinical procedure for nerve repair remains the surgical end-to-end reattachment of the injured nerve, aligning the ends into as close to their original apposition as possible and without tension. This approach offers the best possibility for efficient and effective axonal regeneration and functional recovery. For cases in which there is damage that results in a gap that is too long for tensionless end-to-end repair, nerve grafts are used to support the regeneration of axons. The degree of recovery of function with grafts decreases precipitously with increases in either/both gap-length and the distance from the injury to the target tissues. Treatments that can enhance the number of axons growing, the speed of their growth, and the gap-length they can span are needed. The academic PI has identified a combination of growth factors that significantly and clinically- meaningfully enhances each of these characteristics and can be encapsulated in polymer beads to enable incorporation into grafts for extended-duration of release. The academic PI has demonstrated efficacy of this system in a large animal model. This project aims to develop the fabrication procedures for growth factor encapsulation and impregnation into nerve conduit grafts that could be used clinically. The goals include in vitro and in vivo assessment of the fabricated grafts to validate that they remain effective. This work is necessary to determine the commercial viability of the lab-proven technology.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Clinical Validation of Myoelectric Implant for Intuitive Prosthesis Control
- Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
- Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy
- Developing closed-loop tonic motor activation therapy for treatment of refractory restless legs syndrome
- Engineered microglia for the treatment of Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)